Drug Development and Where Bioanalytical Fits In

Dom has been globe-trotting lately, and he has come back to report in on his adventures with John, as they discuss our global services here at KCAS Bio. They talk about the updates and the latest news from Lyon and the rollout of our collaboration with Crux Laboratories in Melbourne. Most notable was Dom’s trip to Lyon and some of the excitement he experienced there (spoiler: it involves tear gas!!). Our two hosts also discuss the strategy and growth of both our Lyon site, and the new things happening with our collaboration site in Australia. Lots to cover – should be a fun and entertaining episode of the podcast!“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

Dom and John welcome special guests, Habibi Goudarzi and Rochelle Burke to episode #77 of "The Weekly Bioanalysis", where they discuss the progression of bioanalytical needs for non-GLP Studies, from Early PK to readiness for GLP Tox Studies. These specialists from the KCAS Bio team begin with an introduction to all things non-GLP and LC-MS. From there, they discuss the general need for speed and the workflow they have established at KCAS Bio to facilitate rapid turnaround for studies, as well as some of the challenges that can be an obstacle to the speed of studies (issues with tissue analysis, sample size, etc). The four go on to discuss the trends they have seen taking place within LC-MS and the future expectations they have for non-GLP LC-MS/MS.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

For episode #76 of "The Weekly Bioanalysis", Dom and John talk about the popular topic of GLP-1 Analogues - these series of recent blockbuster drugs with multiple applications, as well as some of their bioanalytical challenges. First, the guys go over a little bit of the mechanism of action of GLP-1's, then some of the rules around them and their initial diabetic treatments. They talk about the structures, and a little bit about how they are being used in weight loss (which, of course, is how these drugs have become so popular in mainstream culture now). Finally, they will discuss some of the resulting supply chain issues and even some of the bioanalytical challenges and what the future of these GLP-1 Analogues might be. It's a jam packed show - really an interesting, fascinating topic the guys enjoy discussing. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries. 

CEO of KCAS Bio, John Bucksath, joins Dom and John for a special 75th episode of “The Weekly Bioanalysis” podcast, and he is absolutely delighted to use the special episode to talk about the recent rebrand of KCAS to KCAS Bio! Mr Bucksath and our hosts discuss the reason the rebrand came about, the process our organization took, and some of the initial reactions our team have experienced from our first few outings with the new look and name. Join us as we introduce the new brand and point to it as the first of many steps into the future of our organization!“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

During this episode of “The Weekly Bioanalysis”, Dom and John talk about addressing the needs of rare diseases - some challenges and industry trends they’ve watched take place, and they are joined by guest, Lindsay Rutherford, who has her own personal experience with rare disease and how it can impact lives. As a bioanalytical provider, KCAS Bio of course has a unique take on this topic as well, as rare disease has its own challenges in terms of small sample loads, rapid turnaround of samples to get results out to pharma companies, lack of matrix, etc.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

To kick off the first episode of “The Weekly Bioanalysis” in 2024, Dom and John unveil some fun new things happening at KCAS, by talking about the parallel evolution of the bioanalytical industry and KCAS. Our hosts go way back – almost to “square one” (discussing “What is bioanalysis?” and “How has bioanalysis changed over the years?”. They take a nice little dip back into history and then and then tie it all back to where we are now and what it means about we are going for the future. We hope you enjoy our announcement as much as you enjoy listening to how we’ve evolved as an industry, as well as an organization.“The Weekly Bioanalysis” is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

For the final episode of “The Weekly Bioanalysis” in 2023, Dom and John invited KCAS’s scientific advisory team to join them, as we thought that as we are coming to the end of the year, it might be a good opportunity to introduce a few members of the scientific advisory team who may be involved in some greater capacity with the podcast going forward, as the organization grows and expands. Then our hosts just have a chat about reviewing how 2023 went and what they see coming up in 2024 within the pharmaceutical and biopharmaceutical industries – so a look back, a look at where we are, and a look forward.“The Weekly Bioanalysis” is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Dom and John have been doing this for a long time (for over 70 episodes now, to be exact), but they felt it might be a good idea to jump back to the very beginning and discuss the overarching concept of the Drug Development process and where it is that Bioanalysis fits in. This is somewhat of a response to a recent listener request, but we also feel its important every once in a while to refocus and put all of the things we do at KCAS into perspective against the entire pharmaceutical and biotech industry – from large and small molecule and GLP vs Non-GLP, to all the therapeutic areas with drug development, Dom and John discuss it all on episode #71 of “The Weekly Bioanalysis”"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

It is that time of year once again... the Fall Conference Season! Every industry has its own set of important trade shows and meetings, but for the Pharma, biotech and bioanalytical industries, these conferences are an opportunity for the planet's leading experts to get together and share the newest ways to heal the world. With October almost upon us, Dom and John discuss the upcoming conferences in our industry, and why it might be worth your time to find yourself at more than one of them - it might even be a chance to meet Dom and John there!"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Starting off with a description of Antibody Drug Conjugates (or ADCs, for short), Dom and John dive into this field of the industry and discuss the ways these services have changed over time and even how they've changed recently. They review the role of ADCs in meeting some of the unmet medical needs in oncology and the way they're changing the effectiveness of some of the most modern drugs being developed. The evolution of ADC design for approved medications and indications make it clear that Antibody Drug Conjugates will be a big part of our industry for a long time."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.